We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sanofi-aventis has filed a patent infringement lawsuit in federal court to block the manufacturing and marketing of zolpidem tartrate, a generic version of its blockbuster sleep drug Ambien CR.
One day after the FDA granted first-filer Ranbaxy Pharmaceuticals permission to market valacyclovir hydrochloride tablets, patent holder GlaxoSmithKline quickly moved to stop the generic firm from cutting in on sales of its blockbuster herpes treatment drug, Valtrex.
Despite being the first to win final FDA approval — with 180 days of exclusivity — to manufacture and market generic Focalin, Teva Pharmaceutical still has to prevail in court against Novartis and Celgene.
A Canadian court’s invalidation of a key patent held by Pfizer could open the door to the manufacturing and marketing of atorvastatin tablets, a generic version of Pfizer’s blockbuster cholesterol-lowering drug, Lipitor.
Celgene has filed a patent infringement lawsuit in federal court to block the manufacturing and marketing of generic Thalomid, Barr Laboratories confirmed.
One day after the FDA granted first-filer Ranbaxy Pharmaceuticals permission to market valacyclovir hydrochloride tablets, patent holder GlaxoSmithKline (GSK) quickly moved to stop the generic firm from cutting in on sales of its blockbuster herpes treatment drug, Valtrex.
Manufacturing methods used by Pfizer to produce its top-selling hypertension treatment drug Norvasc do not infringe on patents held by Synthon, a federal district court has ruled.
Despite being the first to win final FDA approval — with 180-days of exclusivity — to manufacture and market generic Focalin, Teva Pharmaceutical still has to prevail in court against Novartis and Celgene.
Apotex wants legal protection from patent infringement liabilities related to the manufacturing and marketing of ranitidine hydrochloride, a generic version of GlaxoSmithKline’s (GSK) Zantac, according to a complaint filed in federal court last week.
The invalidation of a key patent held by Pfizer could open the door to the manufacturing and marketing of atorvastatin tablets, a generic version of Pfizer’s blockbuster cholesterol-lowering drug, Lipitor.